1,925.00p
-1.28%
Close of 9 Nov 2026, in pence
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bioventix
Its shares trade on LSE under the ticker BVXP.L. It has been listed since 29 April 2014. In the fiscal year to 30 June 2026, it reported revenue of £13.0m and net income of £7.6m. At that date it held total assets of £12.8m and shareholders' equity of £11.4m.
Bioventix Plc engages in the development and supply of antibodies. The company is headquartered in Farnham, Surrey. The company went IPO on 2014-04-29. The principal activity of the Company is the development and supply of antibodies. The firm specializes in the development of sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing. The firm's non-vitamin D business consists of antibodies, NT proBNP (heart failure), testosterone, Free Triiodothyronine (FT3) (thyroid hormone), estradiol, and various drugs, such as tetrahydrocannabinol (THC)/cannabis, and progesterone. The firm offers products for indications, such as thyroid, fertility, oncology, cardiac, vitamin D, drug of abuse, infectious disease and miscellaneous. Its sheep hybridoma technology produces cell lines that secrete SMAs. The firm offers a panel of SMAs to 25-OH D and has various 25-OH D2 and 25-OH D3 specific antibodies. The company sells its products through direct sales and through distributors.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 29 Apr 2014
- Employees
- 16
- Website
- bioventix.com ↗
Leadership
Pay as last reported
- Mr. Ian NicholsonIndependent Non-Executive Chairman of the Board£43,549
- Mr. Peter HarrisonChief Executive Officer, Executive Director£387,779
- Mr. Bruce HiscockChief Financial Officer, Executive Director, since 2020£97,334
- Mr. Nicholas MccookeNon-Executive Independent Director£30,000
- Ms. Joanne PisaniNon-Executive Independent Director£30,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Established Reputation: Bioventix PLC has built a strong reputation in the biotechnology industry, known for its high-quality products and expertise in the development of antibodies and assay technologies.
- Unique Technology: The company possesses proprietary technology that enables the production of highly specific and sensitive antibodies, leading to superior diagnostic products.
- Strong Financial Performance: Bioventix PLC has consistently demonstrated solid financial performance, with steady revenue growth and healthy profit margins. This financial stability allows for further investment in research and development.
Weaknesses
- Limited Product Portfolio: Bioventix PLC's product range is relatively focused, primarily targeting the diagnostics market. This narrow focus may pose a risk in terms of dependence on a limited number of products.
- Dependency on Key Customers: The company relies heavily on a few key customers for a significant portion of its revenues. The loss of any major customer could impact its financial performance.
- Vulnerability to Competitive Pressure: The biotechnology industry is highly competitive, and Bioventix PLC faces the risk of competitors developing similar or superior products to gain market share.
Opportunities
- Growing Demand for Diagnostic Tests: The increasing global focus on healthcare and disease management presents an opportunity for Bioventix PLC to expand its market presence and offer its innovative diagnostic products to a broader customer base.
- Expansion into New Markets: The company could explore potential partnerships or acquisitions to enter new geographic markets or diversify its product offering, reducing the risk associated with being too reliant on a single market segment.
- Technological Advancements: Continuous advancements in biotechnology and diagnostic testing methods create opportunities for Bioventix PLC to develop and launch new products that meet evolving customer needs.
Threats
- Regulatory and Compliance Challenges: The biotechnology industry is subject to strict regulations and compliance requirements. Any changes in regulations or failure to comply with existing ones could significantly impact Bioventix PLC's operations and market access.
- Economic Downturns: Economic downturns or recessions can negatively impact healthcare spending, leading to a potential decrease in demand for diagnostic products, which could affect the company's revenue and profitability.
- Intellectual Property Risks: Bioventix PLC's success relies on protecting its intellectual property rights. There is a threat of patent infringements or unauthorized use of its technologies by competitors, which could erode its market share and competitive advantage.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.